On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package $50 million in venture financing extends cash runway into 2027, allowing Tr1X to advance the TRX319 Phase 1/2a study and the ongoing TRX103 Phase 1/2a trial for patients with refractory Crohn’s disease Oct. 14, 2025 -- Tr1X, a clini

Dec. 03, 2025 -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management Dec. 02, 2025 -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibrom

Dec. 01, 2025 -- Juniper Biosciences LLC today announced the closing of an oversubscribed and upsized $40 million seed financing through its parent company, Juniper Radiopharma LLC, co-led by NovaCapital, several high-net-worth individuals, and members of the Club Degli Investitori. “We are thrilled to have the support of a diverse investor base who believe strongly in the promise that radiopharmaceuticals offer to the future of patient care.” said Alex Agnoletto, CEO. “Our founding team bring

Nov. 28, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07

– Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. – Mr. Matteo Renzi, former Prime Minister of Italy has joined the Enlivex Board of Directors. – Enlivex to continue clinical devel

Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI’s November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Sci

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end These agreements ensure BioAtla can maintain operational momentum while completing that process Nov. 21, 2025 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme

- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - Nov. 20, 2025 -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced the first closing of its previously announced private placement (“PIPE”). Additionally, the Company announ

Nov. 19, 2025 -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the receipt of a Notice of Award of a grant from the NIH/NINDS and entry into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation. On September 23, 2025, RespireRx received a Notice of Award from t